why choose us

First received: November 30, 2022

Clinical Trial: MYLUNG Consortium Study Protocol 2

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Carcinoma, Non-Small-Cell Lung

Study Type: Observational [Patient Registry]


Official Title: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Brief Summary: This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Read more